OKYO Pharma Ltd (OKYO) reported positive top-line data from the Phase 2 study of urcosimod to treat Neuropathic Corneal Pain (NCP), the company Wednesday said in a regulatory filing.
OKYO is the first company to conduct a clinical study to treat NCP, a major unmet medical need, it added.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.